Is LXEO or KALV more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat KalVista Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% KalVista Pharmaceuticals N/A -341.44% -111.94%

Does the media favor XERS or LXEO?

In the previous week, Xeris Biopharma had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 3 mentions for Xeris Biopharma and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.31 beat Xeris Biopharma's score of 0.54 indicating that Lexeo Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xeris Biopharma 1 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Lexeo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate LXEO or NNNN?

Lexeo Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 312.09%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than Anbio Biotechnology. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lexeo Therapeutics 1 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 2.89 Anbio Biotechnology 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00

Which has higher earnings and valuation, LXEO or NNNN?

Anbio Biotechnology has higher revenue and earnings than Lexeo Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Lexeo Therapeutics N/A N/A -$99.96M -$1.45 N/A Anbio Biotechnology $8.65M 158.36 $6.40M N/A N/A

Is LXEO or NNNN more profitable?

Anbio Biotechnology's return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Anbio Biotechnology N/A N/A N/A

Is LXEO or AKTS more profitable?

Aktis Oncology's return on equity of 0.00% beat Lexeo Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Aktis Oncology N/A N/A N/A

Does the media prefer LXEO or AKTS?

In the previous week, Aktis Oncology had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 3 mentions for Aktis Oncology and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.31 beat Aktis Oncology's score of 0.39 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Aktis Oncology 1 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Is LXEO or INBX more profitable?

Lexeo Therapeutics' return on equity of -47.48% beat Inhibrx Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets Lexeo Therapeutics N/A -47.48% -41.72% Inhibrx Biosciences N/A -563.90% -72.32%

Does the media prefer LXEO or INBX?

In the previous week, Lexeo Therapeutics and Lexeo Therapeutics both had 2 articles in the media. Lexeo Therapeutics' average media sentiment score of 1.31 beat Inhibrx Biosciences' score of 0.34 indicating that Lexeo Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lexeo Therapeutics 2 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Inhibrx Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Lexeo Therapeutics (LXEO) Competitors

$4.55 -0.14 (-2.99%)

Closing price 04:00 PM Eastern

Extended Trading

$4.56 +0.00 (+0.11%)

As of 07:34 PM Eastern

Compare

LXEO vs. KALV, XERS, NNNN, AKTS, and INBX

Should you buy Lexeo Therapeutics stock or one of its competitors? MarketBeat compares Lexeo Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Lexeo Therapeutics include KalVista Pharmaceuticals (KALV), Xeris Biopharma (XERS), Anbio Biotechnology (NNNN), Aktis Oncology (AKTS), and Inhibrx Biosciences (INBX). These companies are all part of the "pharmaceutical products" industry.

How does Lexeo Therapeutics compare to KalVista Pharmaceuticals?

Lexeo Therapeutics (NASDAQ:LXEO) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

Lexeo Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 312.09%. KalVista Pharmaceuticals has a consensus price target of $33.25, suggesting a potential upside of 23.15%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than KalVista Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
KalVista Pharmaceuticals	1 Sell rating(s)	5 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.22

Lexeo Therapeutics has a beta of 1.42, meaning that its share price is 42% more volatile than the broader market. Comparatively, KalVista Pharmaceuticals has a beta of -0.12, meaning that its share price is 112% less volatile than the broader market.

Lexeo Therapeutics' return on equity of -47.48% beat KalVista Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
KalVista Pharmaceuticals	N/A	-341.44%	-111.94%

Lexeo Therapeutics has higher earnings, but lower revenue than KalVista Pharmaceuticals. KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
KalVista Pharmaceuticals	$1.43M	1,008.07	-$109.52M	-$3.46	N/A

60.7% of Lexeo Therapeutics shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Lexeo Therapeutics had 2 more articles in the media than KalVista Pharmaceuticals. MarketBeat recorded 2 mentions for Lexeo Therapeutics and 0 mentions for KalVista Pharmaceuticals. Lexeo Therapeutics' average media sentiment score of 1.31 beat KalVista Pharmaceuticals' score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Positive
KalVista Pharmaceuticals	Neutral

Summary

Lexeo Therapeutics beats KalVista Pharmaceuticals on 12 of the 14 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Xeris Biopharma?

Xeris Biopharma (NASDAQ:XERS) and Lexeo Therapeutics (NASDAQ:LXEO) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, risk, institutional ownership, earnings, dividends, analyst recommendations, valuation and media sentiment.

Xeris Biopharma has a beta of 0.62, meaning that its stock price is 38% less volatile than the broader market. Comparatively, Lexeo Therapeutics has a beta of 1.42, meaning that its stock price is 42% more volatile than the broader market.

42.8% of Xeris Biopharma shares are held by institutional investors. Comparatively, 60.7% of Lexeo Therapeutics shares are held by institutional investors. 4.4% of Xeris Biopharma shares are held by company insiders. Comparatively, 2.0% of Lexeo Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Xeris Biopharma has a net margin of 3.81% compared to Lexeo Therapeutics' net margin of 0.00%. Xeris Biopharma's return on equity of 735.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Xeris Biopharma	3.81%	735.00%	3.24%
Lexeo Therapeutics	N/A	-47.48%	-41.72%

Xeris Biopharma has higher revenue and earnings than Lexeo Therapeutics. Lexeo Therapeutics is trading at a lower price-to-earnings ratio than Xeris Biopharma, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Xeris Biopharma	$291.85M	5.09	$550K	$0.06	143.33
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A

Xeris Biopharma presently has a consensus target price of $10.80, indicating a potential upside of 25.58%. Lexeo Therapeutics has a consensus target price of $18.75, indicating a potential upside of 312.09%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Lexeo Therapeutics is more favorable than Xeris Biopharma.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Xeris Biopharma	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89

In the previous week, Xeris Biopharma had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 3 mentions for Xeris Biopharma and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.31 beat Xeris Biopharma's score of 0.54 indicating that Lexeo Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Xeris Biopharma	1 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Lexeo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Xeris Biopharma beats Lexeo Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Anbio Biotechnology?

Lexeo Therapeutics (NASDAQ:LXEO) and Anbio Biotechnology (NASDAQ:NNNN) are both small-cap pharmaceutical products companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, media sentiment, profitability, analyst recommendations, institutional ownership, dividends, valuation and risk.

In the previous week, Lexeo Therapeutics had 2 more articles in the media than Anbio Biotechnology. MarketBeat recorded 2 mentions for Lexeo Therapeutics and 0 mentions for Anbio Biotechnology. Lexeo Therapeutics' average media sentiment score of 1.31 beat Anbio Biotechnology's score of 0.00 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Lexeo Therapeutics	Positive
Anbio Biotechnology	Neutral

Lexeo Therapeutics has a beta of 1.42, indicating that its share price is 42% more volatile than the broader market. Comparatively, Anbio Biotechnology has a beta of 5.15, indicating that its share price is 415% more volatile than the broader market.

Lexeo Therapeutics currently has a consensus price target of $18.75, indicating a potential upside of 312.09%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts clearly believe Lexeo Therapeutics is more favorable than Anbio Biotechnology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Anbio Biotechnology	0 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	2.00

Anbio Biotechnology has higher revenue and earnings than Lexeo Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Anbio Biotechnology	$8.65M	158.36	$6.40M	N/A	N/A

Anbio Biotechnology's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Anbio Biotechnology	N/A	N/A	N/A

60.7% of Lexeo Therapeutics shares are owned by institutional investors. 2.0% of Lexeo Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Summary

Lexeo Therapeutics beats Anbio Biotechnology on 8 of the 13 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Aktis Oncology?

Lexeo Therapeutics (NASDAQ:LXEO) and Aktis Oncology (NASDAQ:AKTS) are both small-cap pharmaceutical products companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, profitability, earnings, risk, media sentiment, valuation, dividends and analyst recommendations.

Aktis Oncology has higher revenue and earnings than Lexeo Therapeutics. Aktis Oncology is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Aktis Oncology	$6.50M	196.84	-$63.73M	-$0.38	N/A

Aktis Oncology's return on equity of 0.00% beat Lexeo Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Aktis Oncology	N/A	N/A	N/A

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 28.8% of Aktis Oncology shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Lexeo Therapeutics presently has a consensus price target of $18.75, suggesting a potential upside of 312.09%. Aktis Oncology has a consensus price target of $34.60, suggesting a potential upside of 44.41%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Lexeo Therapeutics is more favorable than Aktis Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Aktis Oncology	1 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.88

In the previous week, Aktis Oncology had 1 more articles in the media than Lexeo Therapeutics. MarketBeat recorded 3 mentions for Aktis Oncology and 2 mentions for Lexeo Therapeutics. Lexeo Therapeutics' average media sentiment score of 1.31 beat Aktis Oncology's score of 0.39 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Aktis Oncology	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Lexeo Therapeutics and Aktis Oncology tied by winning 6 of the 12 factors compared between the two stocks.

How does Lexeo Therapeutics compare to Inhibrx Biosciences?

Lexeo Therapeutics (NASDAQ:LXEO) and Inhibrx Biosciences (NASDAQ:INBX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, profitability, institutional ownership, dividends, risk, earnings, analyst recommendations and valuation.

Lexeo Therapeutics currently has a consensus price target of $18.75, suggesting a potential upside of 312.09%. Inhibrx Biosciences has a consensus price target of $150.00, suggesting a potential upside of 78.38%. Given Lexeo Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Lexeo Therapeutics is more favorable than Inhibrx Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lexeo Therapeutics	1 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	1 Strong Buy rating(s)	2.89
Inhibrx Biosciences	1 Sell rating(s)	3 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	2.33

Lexeo Therapeutics' return on equity of -47.48% beat Inhibrx Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lexeo Therapeutics	N/A	-47.48%	-41.72%
Inhibrx Biosciences	N/A	-563.90%	-72.32%

Lexeo Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Inhibrx Biosciences has a beta of 3.41, suggesting that its stock price is 241% more volatile than the broader market.

In the previous week, Lexeo Therapeutics and Lexeo Therapeutics both had 2 articles in the media. Lexeo Therapeutics' average media sentiment score of 1.31 beat Inhibrx Biosciences' score of 0.34 indicating that Lexeo Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lexeo Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Inhibrx Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

60.7% of Lexeo Therapeutics shares are held by institutional investors. Comparatively, 82.5% of Inhibrx Biosciences shares are held by institutional investors. 2.0% of Lexeo Therapeutics shares are held by company insiders. Comparatively, 18.3% of Inhibrx Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Lexeo Therapeutics has higher earnings, but lower revenue than Inhibrx Biosciences. Inhibrx Biosciences is trading at a lower price-to-earnings ratio than Lexeo Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lexeo Therapeutics	N/A	N/A	-$99.96M	-$1.45	N/A
Inhibrx Biosciences	$1.30M	948.92	-$140.05M	-$8.39	N/A

Summary

Lexeo Therapeutics beats Inhibrx Biosciences on 8 of the 12 factors compared between the two stocks.

Get Lexeo Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding LXEO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

LXEO vs. The Competition

Export

Metric	Lexeo Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$368.27M	$3.04B	$6.78B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.36%
P/E Ratio	N/A	20.20	27.10	23.96
Price / Sales	N/A	782.84	573.91	112.12
Price / Cash	N/A	27.11	26.68	47.27
Price / Book	1.35	4.20	10.66	6.14
Net Income	-$99.96M	$65.94M	$3.60B	$331.74M
7 Day Performance	-1.94%	-3.04%	-1.51%	-1.72%
1 Month Performance	-7.71%	-1.30%	1.11%	-1.44%
1 Year Performance	9.64%	16.06%	23.77%	16.97%

Lexeo Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
LXEO Lexeo Therapeutics	2.0979 of 5 stars	$4.55 -3.0%	$18.75 +312.1%	+13.0%	$368.27M	N/A	N/A	58	Positive News
KALV KalVista Pharmaceuticals	N/A	$27.00 flat	$33.25 +23.1%	N/A	$1.44B	$1.43M	N/A	100
XERS Xeris Biopharma	3.2718 of 5 stars	$8.21 +0.6%	$10.80 +31.5%	+72.2%	$1.42B	$291.85M	136.75	290
NNNN Anbio Biotechnology	0.3006 of 5 stars	$9.59 -3.8%	N/A	N/A	$1.40B	$8.65M	N/A	27	Positive News
AKTS Aktis Oncology	2.2554 of 5 stars	$26.00 +1.6%	$34.60 +33.1%	N/A	$1.39B	$6.50M	N/A	76	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:LXEO) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. KALV, XERS, NNNN, AKTS, and INBX

How does Lexeo Therapeutics compare to KalVista Pharmaceuticals?

Summary

How does Lexeo Therapeutics compare to Xeris Biopharma?

Summary

How does Lexeo Therapeutics compare to Anbio Biotechnology?

Summary

How does Lexeo Therapeutics compare to Aktis Oncology?

Summary

How does Lexeo Therapeutics compare to Inhibrx Biosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Lexeo Therapeutics (LXEO) Competitors

LXEO vs. KALV, XERS, NNNN, AKTS, and INBX

How does Lexeo Therapeutics compare to KalVista Pharmaceuticals?

Do analysts rate LXEO or KALV?

Which has more volatility & risk, LXEO or KALV?

Is LXEO or KALV more profitable?

Which has preferable valuation & earnings, LXEO or KALV?

Do insiders & institutionals hold more shares of LXEO or KALV?

Does the media prefer LXEO or KALV?

Summary

How does Lexeo Therapeutics compare to Xeris Biopharma?

Which has more risk & volatility, XERS or LXEO?

Do insiders & institutionals believe in XERS or LXEO?

Is XERS or LXEO more profitable?

Which has higher valuation and earnings, XERS or LXEO?

Do analysts recommend XERS or LXEO?

Does the media favor XERS or LXEO?

Summary

How does Lexeo Therapeutics compare to Anbio Biotechnology?

Does the media prefer LXEO or NNNN?

Which has more volatility and risk, LXEO or NNNN?

Do analysts rate LXEO or NNNN?

Which has higher earnings and valuation, LXEO or NNNN?

Is LXEO or NNNN more profitable?

Do insiders and institutionals believe in LXEO or NNNN?

Summary

How does Lexeo Therapeutics compare to Aktis Oncology?

Which has higher earnings and valuation, LXEO or AKTS?

Is LXEO or AKTS more profitable?

Do institutionals & insiders have more ownership in LXEO or AKTS?

Do analysts recommend LXEO or AKTS?

Does the media prefer LXEO or AKTS?

Summary

How does Lexeo Therapeutics compare to Inhibrx Biosciences?

Do analysts recommend LXEO or INBX?

Is LXEO or INBX more profitable?

Which has more risk & volatility, LXEO or INBX?

Does the media prefer LXEO or INBX?

Do institutionals and insiders have more ownership in LXEO or INBX?

Which has preferable valuation and earnings, LXEO or INBX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

LXEO vs. The Competition

Lexeo Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools